PMID- 36210439
OWN - NLM
STAT- MEDLINE
DCOM- 20221011
LR  - 20221024
IS  - 1757-6512 (Electronic)
IS  - 1757-6512 (Linking)
VI  - 13
IP  - 1
DP  - 2022 Oct 9
TI  - Unrelated cord blood transplantation vs. HLA-matched sibling transplantation for 
      adults with B-cell acute lymphoblastic leukemia in complete remission: superior 
      OS for patients with long-term survival.
PG  - 500
LID - 10.1186/s13287-022-03186-3 [doi]
LID - 500
AB  - BACKGROUND: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an 
      important curative therapy for adult acute lymphoblastic leukemia (ALL). For 
      patients who lack a human leukocyte antigen (HLA)-matched sibling donor, 
      unrelated cord blood (UCB) is an alternative graft option. Previous studies have 
      focused mainly on all T- and B-cell ALL (B-ALL) patients, while data related 
      specifically to adult B-ALL patients after UCB transplantation (UCBT) are scarce. 
      METHODS: We retrospectively compared the outcomes of UCBT and HLA-matched sibling 
      transplantation (MST) in the treatment of adult B-ALL patients in complete 
      remission (CR) at our center. From June 2006 to December 2020, 156 adult B-ALL 
      patients who achieved CR before transplantation were enrolled. The main clinical 
      outcomes of UCBT and MST were analyzed. RESULTS: Hematopoietic recovery was 
      significantly faster in MST recipients than in UCBT recipients. Higher incidences 
      of grades II-IV and III-IV acute graft-versus host disease (aGVHD) were found in 
      UCBT recipients (P < 0.001 and = 0.03), while a lower incidence of extensive 
      chronic GVHD (cGVHD) was found in UCBT recipients (P < 0.001). The cumulative 
      incidences of 2-year non-relapse mortality (NRM), 2-year relapse, 5-year 
      disease-free survival (DFS) and 5-year GVHD-free relapse-free survival (GRFS) 
      were comparable between MST and UCBT recipients. The overall survival (OS) during 
      the first 700 days was similar between the MST and UCBT groups, while the OS of 
      patients with a survival time of more than 700 days in the UCBT group was better 
      than that in the MST group according to multivariate analysis (P = 0.03). 
      CONCLUSIONS: Our study shows that when treating adult B-ALL patients in CR, UCBT 
      can achieve comparable effects as MST, may provide superior OS for patients with 
      long-term survival, and should be considered a good alternative.
CI  - (c) 2022. The Author(s).
FAU - Sun, Guangyu
AU  - Sun G
AD  - Department of Hematology, The First Affiliated Hospital of University of Science 
      and Technology of China, Division of Life Sciences and Medicine, University of 
      Science and Technology of China, Hefei, 230001, Anhui, China.
AD  - Anhui Provincial Key Laboratory of Blood Research and Applications, Hefei, China.
AD  - Blood and Cell Therapy Institute, Division of Life Sciences and Medicine, 
      University of Science and Technology of China, Hefei, China.
FAU - Tang, Baolin
AU  - Tang B
AD  - Department of Hematology, The First Affiliated Hospital of University of Science 
      and Technology of China, Division of Life Sciences and Medicine, University of 
      Science and Technology of China, Hefei, 230001, Anhui, China.
AD  - Anhui Provincial Key Laboratory of Blood Research and Applications, Hefei, China.
AD  - Blood and Cell Therapy Institute, Division of Life Sciences and Medicine, 
      University of Science and Technology of China, Hefei, China.
FAU - Song, Kaidi
AU  - Song K
AD  - Department of Hematology, The First Affiliated Hospital of University of Science 
      and Technology of China, Division of Life Sciences and Medicine, University of 
      Science and Technology of China, Hefei, 230001, Anhui, China.
FAU - Wu, Yue
AU  - Wu Y
AD  - Department of Hematology, The First Affiliated Hospital of University of Science 
      and Technology of China, Division of Life Sciences and Medicine, University of 
      Science and Technology of China, Hefei, 230001, Anhui, China.
FAU - Tu, Meijuan
AU  - Tu M
AD  - Department of Hematology, The First Affiliated Hospital of University of Science 
      and Technology of China, Division of Life Sciences and Medicine, University of 
      Science and Technology of China, Hefei, 230001, Anhui, China.
FAU - Wan, Xiang
AU  - Wan X
AD  - Department of Hematology, The First Affiliated Hospital of University of Science 
      and Technology of China, Division of Life Sciences and Medicine, University of 
      Science and Technology of China, Hefei, 230001, Anhui, China.
AD  - Anhui Provincial Key Laboratory of Blood Research and Applications, Hefei, China.
AD  - Blood and Cell Therapy Institute, Division of Life Sciences and Medicine, 
      University of Science and Technology of China, Hefei, China.
FAU - Yao, Wen
AU  - Yao W
AD  - Department of Hematology, The First Affiliated Hospital of University of Science 
      and Technology of China, Division of Life Sciences and Medicine, University of 
      Science and Technology of China, Hefei, 230001, Anhui, China.
FAU - Geng, Liangquan
AU  - Geng L
AD  - Department of Hematology, The First Affiliated Hospital of University of Science 
      and Technology of China, Division of Life Sciences and Medicine, University of 
      Science and Technology of China, Hefei, 230001, Anhui, China.
FAU - Qiang, Ping
AU  - Qiang P
AD  - Department of Hematology, The First Affiliated Hospital of University of Science 
      and Technology of China, Division of Life Sciences and Medicine, University of 
      Science and Technology of China, Hefei, 230001, Anhui, China.
FAU - Zhu, Xiaoyu
AU  - Zhu X
AD  - Department of Hematology, The First Affiliated Hospital of University of Science 
      and Technology of China, Division of Life Sciences and Medicine, University of 
      Science and Technology of China, Hefei, 230001, Anhui, China. 
      xiaoyuz@ustc.edu.cn.
AD  - Anhui Provincial Key Laboratory of Blood Research and Applications, Hefei, China. 
      xiaoyuz@ustc.edu.cn.
AD  - Blood and Cell Therapy Institute, Division of Life Sciences and Medicine, 
      University of Science and Technology of China, Hefei, China. xiaoyuz@ustc.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20221009
PL  - England
TA  - Stem Cell Res Ther
JT  - Stem cell research & therapy
JID - 101527581
RN  - 0 (HLA Antigens)
RN  - 0 (Histocompatibility Antigens Class II)
SB  - IM
MH  - Acute Disease
MH  - Adult
MH  - *Burkitt Lymphoma
MH  - *Cord Blood Stem Cell Transplantation
MH  - *Graft vs Host Disease
MH  - HLA Antigens
MH  - *Hematopoietic Stem Cell Transplantation
MH  - Histocompatibility Antigens Class II
MH  - Humans
MH  - *Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy
MH  - Retrospective Studies
MH  - Siblings
PMC - PMC9549614
OTO - NOTNLM
OT  - Acute lymphoblastic leukemia
OT  - Hematopoietic stem cell transplantation
OT  - Matched sibling transplantation
OT  - Unrelated cord blood transplantation
COIS- The authors declare no competing interests.
EDAT- 2022/10/10 06:00
MHDA- 2022/10/12 06:00
PMCR- 2022/10/09
CRDT- 2022/10/09 23:23
PHST- 2022/05/05 00:00 [received]
PHST- 2022/09/30 00:00 [accepted]
PHST- 2022/10/09 23:23 [entrez]
PHST- 2022/10/10 06:00 [pubmed]
PHST- 2022/10/12 06:00 [medline]
PHST- 2022/10/09 00:00 [pmc-release]
AID - 10.1186/s13287-022-03186-3 [pii]
AID - 3186 [pii]
AID - 10.1186/s13287-022-03186-3 [doi]
PST - epublish
SO  - Stem Cell Res Ther. 2022 Oct 9;13(1):500. doi: 10.1186/s13287-022-03186-3.